首页 > 最新文献

Reumatologia最新文献

英文 中文
Low serum zonulin level in patients with systemic sclerosis. 系统性硬化症患者血清zonulin水平低。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-06 DOI: 10.5114/reum/194846
Karolina Wąż, Eugeniusz J Kucharz, Magdalena Kopeć-Mędrek, Ewelina Machura-Porębska, Robert Pieczyrak, Przemysław Kotyla
{"title":"Low serum zonulin level in patients with systemic sclerosis.","authors":"Karolina Wąż, Eugeniusz J Kucharz, Magdalena Kopeć-Mędrek, Ewelina Machura-Porębska, Robert Pieczyrak, Przemysław Kotyla","doi":"10.5114/reum/194846","DOIUrl":"10.5114/reum/194846","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"389-390"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Key personal insights and changing needs of osteoarthritis patients: an international quantitative survey analysis.
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-12-19 DOI: 10.5114/reum/195324
Zoltán Szekanecz, Diana Osadcii-Zaiat, András Bajkó, Hajnalka Minda, Dóra Szerencsés

Introduction: Osteoarthritis (OA) presents significant challenges, imposing limitations on patients' daily activities. Factors such as restricted mobility, sedentary lifestyles, social isolation, and weight gain can exacerbate the difficulties faced by these individuals. Our study aimed to identify the needs and personal challenges faced by individuals with OA, and the impact of the COVID-19 pandemic.

Material and methods: The research included a quantitative survey and a workshop involving a Scientific Leader Team. The quantitative survey was conducted among 400 patients in Bulgaria, Romania, Serbia, and Kazakhstan. All enrolled participants had experienced chronic musculoskeletal pain due to OA for at least three years and had received treatment with topical or oral medications. The cross-country workshop, conducted via Zoom, brought together prominent rheumatologists to discuss the survey results and explore patient support opportunities with healthcare providers.

Results: Over 60% of respondents reported that poor locomotor function adversely affected their daily activities. More than 50% stated that they had delayed treatment due to concerns about potential side effects, while over half expressed a desire for rapid pain relief. Approximately 30% of patients reported an increase in musculoskeletal complaints following the onset of the COVID-19 pandemic. The proportion of online consultations rose significantly, increasing from 5% before the pandemic to 12% during it, before stabilizing at 9% in the post-pandemic period.

Conclusions: Patients with OA face considerable limitations in their daily lives, with a strong preference for immediate pain relief. Concerns about side effects lead many to postpone treatment. Over-the-counter anti-inflammatory creams and prescription oral anti-inflammatory drugs are the most used therapies. The pandemic negatively affected OA symptoms. Furthermore, the use of online channels for OA patient care increased during the COVID-19 pandemic.

{"title":"Key personal insights and changing needs of osteoarthritis patients: an international quantitative survey analysis.","authors":"Zoltán Szekanecz, Diana Osadcii-Zaiat, András Bajkó, Hajnalka Minda, Dóra Szerencsés","doi":"10.5114/reum/195324","DOIUrl":"10.5114/reum/195324","url":null,"abstract":"<p><strong>Introduction: </strong>Osteoarthritis (OA) presents significant challenges, imposing limitations on patients' daily activities. Factors such as restricted mobility, sedentary lifestyles, social isolation, and weight gain can exacerbate the difficulties faced by these individuals. Our study aimed to identify the needs and personal challenges faced by individuals with OA, and the impact of the COVID-19 pandemic.</p><p><strong>Material and methods: </strong>The research included a quantitative survey and a workshop involving a Scientific Leader Team. The quantitative survey was conducted among 400 patients in Bulgaria, Romania, Serbia, and Kazakhstan. All enrolled participants had experienced chronic musculoskeletal pain due to OA for at least three years and had received treatment with topical or oral medications. The cross-country workshop, conducted via Zoom, brought together prominent rheumatologists to discuss the survey results and explore patient support opportunities with healthcare providers.</p><p><strong>Results: </strong>Over 60% of respondents reported that poor locomotor function adversely affected their daily activities. More than 50% stated that they had delayed treatment due to concerns about potential side effects, while over half expressed a desire for rapid pain relief. Approximately 30% of patients reported an increase in musculoskeletal complaints following the onset of the COVID-19 pandemic. The proportion of online consultations rose significantly, increasing from 5% before the pandemic to 12% during it, before stabilizing at 9% in the post-pandemic period.</p><p><strong>Conclusions: </strong>Patients with OA face considerable limitations in their daily lives, with a strong preference for immediate pain relief. Concerns about side effects lead many to postpone treatment. Over-the-counter anti-inflammatory creams and prescription oral anti-inflammatory drugs are the most used therapies. The pandemic negatively affected OA symptoms. Furthermore, the use of online channels for OA patient care increased during the COVID-19 pandemic.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 6","pages":"398-404"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review. 肝病风湿病患者药物治疗中的药理学考虑因素:简述综述。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-16 DOI: 10.5114/reum/191791
Saeedeh Shenavandeh, Seyed Alireza Taghavi, AliAkbar Nekooeian, Maryam Moini

The presence of chronic liver diseases such as metabolic dysfunction-associated steatosis liver disease, viral hepatitis, and cirrhosis may affect the treatment plan in patients with rheumatologic disorders, with concern about the adverse effects of the rheumatic medications on the course of liver disease. Advanced liver disease can change the elimination and activation of many drugs. In addition, there are concerns about the risk of viral reactivation after using biologics and immunosuppressants in patients with chronic viral hepatitis. This narrative review will assess the considerations that should be made before starting the most frequently used drugs in all common rheumatic diseases and patients with chronic liver diseases including chronic viral hepatitis.

慢性肝病(如代谢功能障碍相关性脂肪肝肝病、病毒性肝炎和肝硬化)的存在可能会影响风湿病患者的治疗方案,人们担心风湿病药物会对肝病病程产生不良影响。晚期肝病会改变许多药物的消除和激活。此外,人们还担心慢性病毒性肝炎患者使用生物制剂和免疫抑制剂后病毒再激活的风险。本叙述性综述将评估所有常见风湿病和慢性肝病(包括慢性病毒性肝炎)患者在开始使用最常用药物前应注意的事项。
{"title":"Pharmacological considerations in pharmacotherapy of rheumatology patients with liver disease: a brief narrative review.","authors":"Saeedeh Shenavandeh, Seyed Alireza Taghavi, AliAkbar Nekooeian, Maryam Moini","doi":"10.5114/reum/191791","DOIUrl":"https://doi.org/10.5114/reum/191791","url":null,"abstract":"<p><p>The presence of chronic liver diseases such as metabolic dysfunction-associated steatosis liver disease, viral hepatitis, and cirrhosis may affect the treatment plan in patients with rheumatologic disorders, with concern about the adverse effects of the rheumatic medications on the course of liver disease. Advanced liver disease can change the elimination and activation of many drugs. In addition, there are concerns about the risk of viral reactivation after using biologics and immunosuppressants in patients with chronic viral hepatitis. This narrative review will assess the considerations that should be made before starting the most frequently used drugs in all common rheumatic diseases and patients with chronic liver diseases including chronic viral hepatitis.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 4","pages":"282-293"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and laboratory pattern of patients with systemic lupus erythematosus seropositive for rheumatoid factor. 类风湿因子血清反应阳性的系统性红斑狼疮患者的临床和实验室模式。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-16 DOI: 10.5114/reum/192613
Oleg Iaremenko, Galyna Protsenko, Vitalii Dubas, Daria Koliadenko

Introduction: The aim of the study was to investigate the associations between the presence and level of rheumatoid factor (RF) in the blood serum and the clinical and laboratory characteristics of patients with systemic lupus erythematosus (SLE).

Material and methods: This retrospective tricentric cross-sectional study analyzed a Ukrainian contingent of SLE patients. Medical records of 495 patients were evaluated. Rheumatoid factor serum concentration was tested in 206 of them (41.6%) using turbidimetry technique. Clinical manifestations, routine laboratory parameters, specific immunological tests, disease activity (SLEDAI-2K), and damage indices (SLICC/ACR DI) were evaluated.

Results: Our study revealed that RF was elevated in 27.7% of patients. The RF-positive patients experienced a longer delay in SLE diagnosis (2.0 vs. 0.5 years, p = 0.046), less frequent kidney involvement (42.1% vs. 59.4%, p = 0.045) and fever (42.1% vs. 59.2%, p = 0.046), and more frequent lymphadenopathy (59.6% vs. 42.3%, p = 0.039) compared to RF-negative patients. Patients with RF positivity had higher levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and antinuclear antibody (ANA) titer, and were more frequently positive for antibodies to Ro/SSA and La/SSB. Rheumatoid factor concentration directly correlated with CRP (r = 0.318; p < 0.01) and ESR (r = 0.228; p = 0.04) levels. However, no associations were found between RF levels and SLEDAI-2K, joint involvement frequency, SLICC/ACR DI or drug therapy content. Univariate logistic regression analysis showed that RF positivity was independently associated with lymphadenopathy, presence of anti-Ro/SSA and anti-La/SSB antibodies, and negatively associated with kidney involvement.

Conclusions: In RF-seropositive SLE patients (approximately 28%), the diagnosis is established later compared to RF-seronegative ones; kidney involvement and fever are less common, while lymphadenopathy develops more frequently. Rheumatoid factor seropositivity is associated with higher levels of ESR, CRP, ANA, and the presence of antibodies to Ro/SSA and La/SSB. According to the results of univariate logistic regression analysis, an independent association with RF positivity was confirmed only for kidney involvement, lymphadenopathy, and antibodies to Ro/SSA and La/SSB.

导言本研究旨在探讨血清中类风湿因子(RF)的存在和水平与系统性红斑狼疮(SLE)患者的临床和实验室特征之间的关联:这项回顾性三中心横断面研究分析了乌克兰的系统性红斑狼疮患者。研究评估了 495 名患者的医疗记录。采用比浊法检测了其中206名患者(41.6%)的类风湿因子血清浓度。对临床表现、常规实验室参数、特异性免疫学检测、疾病活动性(SLEDAI-2K)和损害指数(SLICC/ACR DI)进行了评估:我们的研究显示,27.7%的患者RF升高。与RF阴性患者相比,RF阳性患者的系统性红斑狼疮诊断延迟时间更长(2.0年 vs. 0.5年,p = 0.046),肾脏受累(42.1% vs. 59.4%,p = 0.045)和发热(42.1% vs. 59.2%,p = 0.046)的发生率更低,淋巴结病(59.6% vs. 42.3%,p = 0.039)的发生率更高。类风湿因子阳性患者的 C 反应蛋白(CRP)、红细胞沉降率(ESR)和抗核抗体(ANA)滴度水平较高,Ro/SSA 和 La/SSB 抗体阳性率较高。类风湿因子浓度与 CRP(r = 0.318;p < 0.01)和 ESR(r = 0.228;p = 0.04)水平直接相关。然而,RF水平与SLEDAI-2K、关节受累频率、SLICC/ACR DI或药物治疗内容之间没有关联。单变量逻辑回归分析显示,RF阳性与淋巴结病、抗Ro/SSA和抗La/SSB抗体的存在独立相关,与肾脏受累呈负相关:在类风湿因子血清阳性的系统性红斑狼疮患者中(约占28%),与类风湿因子血清阴性的患者相比,确诊时间较晚;肾脏受累和发热较少见,而淋巴结病变则更常见。类风湿因子血清阳性与较高水平的血沉、CRP、ANA 以及 Ro/SSA 和 La/SSB 抗体有关。根据单变量逻辑回归分析的结果,只有肾脏受累、淋巴结病、Ro/SSA 和 La/SSB 抗体与类风湿因子阳性有独立关联。
{"title":"Clinical and laboratory pattern of patients with systemic lupus erythematosus seropositive for rheumatoid factor.","authors":"Oleg Iaremenko, Galyna Protsenko, Vitalii Dubas, Daria Koliadenko","doi":"10.5114/reum/192613","DOIUrl":"https://doi.org/10.5114/reum/192613","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to investigate the associations between the presence and level of rheumatoid factor (RF) in the blood serum and the clinical and laboratory characteristics of patients with systemic lupus erythematosus (SLE).</p><p><strong>Material and methods: </strong>This retrospective tricentric cross-sectional study analyzed a Ukrainian contingent of SLE patients. Medical records of 495 patients were evaluated. Rheumatoid factor serum concentration was tested in 206 of them (41.6%) using turbidimetry technique. Clinical manifestations, routine laboratory parameters, specific immunological tests, disease activity (SLEDAI-2K), and damage indices (SLICC/ACR DI) were evaluated.</p><p><strong>Results: </strong>Our study revealed that RF was elevated in 27.7% of patients. The RF-positive patients experienced a longer delay in SLE diagnosis (2.0 vs. 0.5 years, <i>p</i> = 0.046), less frequent kidney involvement (42.1% vs. 59.4%, <i>p</i> = 0.045) and fever (42.1% vs. 59.2%, <i>p</i> = 0.046), and more frequent lymphadenopathy (59.6% vs. 42.3%, <i>p</i> = 0.039) compared to RF-negative patients. Patients with RF positivity had higher levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and antinuclear antibody (ANA) titer, and were more frequently positive for antibodies to Ro/SSA and La/SSB. Rheumatoid factor concentration directly correlated with CRP (<i>r</i> = 0.318; <i>p</i> < 0.01) and ESR (<i>r</i> = 0.228; <i>p</i> = 0.04) levels. However, no associations were found between RF levels and SLEDAI-2K, joint involvement frequency, SLICC/ACR DI or drug therapy content. Univariate logistic regression analysis showed that RF positivity was independently associated with lymphadenopathy, presence of anti-Ro/SSA and anti-La/SSB antibodies, and negatively associated with kidney involvement.</p><p><strong>Conclusions: </strong>In RF-seropositive SLE patients (approximately 28%), the diagnosis is established later compared to RF-seronegative ones; kidney involvement and fever are less common, while lymphadenopathy develops more frequently. Rheumatoid factor seropositivity is associated with higher levels of ESR, CRP, ANA, and the presence of antibodies to Ro/SSA and La/SSB. According to the results of univariate logistic regression analysis, an independent association with RF positivity was confirmed only for kidney involvement, lymphadenopathy, and antibodies to Ro/SSA and La/SSB.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 4","pages":"226-234"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A proliferation-inducing ligand (APRIL) level among risk factors of ocular involvement in patients with Behçet's disease. 贝赫切特病患者眼部受累风险因素中的增殖诱导配体(APRIL)水平。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-06 DOI: 10.5114/reum/194113
Rasha M Ghaleb, Hanan S Gad, Mohamed I Abdallah, Zaki M Zaki, Jehan A Mahmoud

Introduction: Ocular involvement is quite common in Behçet's disease (BD) and may cause crucial functional complications. Even though the mechanisms of BD remain unclear, advances in genetic and immunological fields have improved our understanding of the immunopathogenesis of BD ocular involvement. Little is known about the expression of a proliferation-inducing ligand (APRIL) in terms of ocular involvement in BD. The objective of this study was to determine whether serum APRIL concentrations are associated with ocular involvement in patients with BD.

Material and methods: The study included 60 patients diagnosed with BD matched by age and sex to 30 healthy individuals. Every patient underwent a clinical evaluation, and the Behçet's Disease Current Activity Form (BDCAF) was utilized to quantify disease activity. All patients underwent a comprehensive ophthalmological assessment. Serum APRIL was assessed for patients as well as controls.

Results: One or more ocular manifestations were found in 42 BD patients (70%), while 18 patients (30%) had no ocular involvement. The mean level of serum APRIL levels was markedly elevated in BD patients, particularly those with ocular involvement, compared to both BD patients without ocular involvement and healthy individuals. A statistically significant association was determined between high APRIL concentration and development of uveitis, cataract, and hypopyon. Cutaneous lesions and arthritis were strong independent predictors for ocular involvement in BD patients.

Conclusions: Overexpression of APRIL in patients with BD, particularly in terms of uveitis, cataract, and hypopyon, lends credence to the idea that B cell activating factors have an important function in BD. These findings may indicate that serum APRIL concentrations can differentiate a clinical subgroup of BD patients with ocular disease. As a result, finding a new therapeutic strategy targeting the APRIL pathway might be beneficial in BD patients suffering from ocular involvement.

眼部受累在behet病(BD)中很常见,并可能导致重要的功能并发症。尽管双相障碍的发病机制尚不清楚,但遗传学和免疫学领域的进展使我们对双相障碍眼部受累的免疫发病机制有了更深入的了解。关于增殖诱导配体(四月份)在BD患者眼部受累方面的表达知之甚少。本研究的目的是确定血清四月份浓度是否与BD患者的眼部受累有关。材料和方法:本研究包括60名年龄和性别匹配的BD患者和30名健康个体。每位患者都进行了临床评估,并使用behet疾病当前活动表(BDCAF)来量化疾病活动。所有患者都接受了全面的眼科评估。对患者和对照组的血清四月进行评估。结果:42例(70%)BD患者出现一种或多种眼部表现,18例(30%)患者无眼部受累。与没有眼部受累的BD患者和健康个体相比,BD患者,特别是眼部受累的患者血清APRIL平均水平显著升高。高APRIL浓度与葡萄膜炎、白内障和低视之间存在统计学上显著的关联。皮肤病变和关节炎是BD患者眼部受累的独立预测因素。结论:在双相障碍患者中,特别是在葡萄膜炎、白内障和近视患者中,APRIL的过表达证实了B细胞激活因子在双相障碍中具有重要功能。这些发现可能表明血清APRIL浓度可以区分患有眼部疾病的双相障碍患者的临床亚群。因此,寻找一种新的靶向APRIL通路的治疗策略可能对患有眼部受累的BD患者有益。
{"title":"A proliferation-inducing ligand (APRIL) level among risk factors of ocular involvement in patients with Behçet's disease.","authors":"Rasha M Ghaleb, Hanan S Gad, Mohamed I Abdallah, Zaki M Zaki, Jehan A Mahmoud","doi":"10.5114/reum/194113","DOIUrl":"10.5114/reum/194113","url":null,"abstract":"<p><strong>Introduction: </strong>Ocular involvement is quite common in Behçet's disease (BD) and may cause crucial functional complications. Even though the mechanisms of BD remain unclear, advances in genetic and immunological fields have improved our understanding of the immunopathogenesis of BD ocular involvement. Little is known about the expression of a proliferation-inducing ligand (APRIL) in terms of ocular involvement in BD. The objective of this study was to determine whether serum APRIL concentrations are associated with ocular involvement in patients with BD.</p><p><strong>Material and methods: </strong>The study included 60 patients diagnosed with BD matched by age and sex to 30 healthy individuals. Every patient underwent a clinical evaluation, and the Behçet's Disease Current Activity Form (BDCAF) was utilized to quantify disease activity. All patients underwent a comprehensive ophthalmological assessment. Serum APRIL was assessed for patients as well as controls.</p><p><strong>Results: </strong>One or more ocular manifestations were found in 42 BD patients (70%), while 18 patients (30%) had no ocular involvement. The mean level of serum APRIL levels was markedly elevated in BD patients, particularly those with ocular involvement, compared to both BD patients without ocular involvement and healthy individuals. A statistically significant association was determined between high APRIL concentration and development of uveitis, cataract, and hypopyon. Cutaneous lesions and arthritis were strong independent predictors for ocular involvement in BD patients.</p><p><strong>Conclusions: </strong>Overexpression of APRIL in patients with BD, particularly in terms of uveitis, cataract, and hypopyon, lends credence to the idea that B cell activating factors have an important function in BD. These findings may indicate that serum APRIL concentrations can differentiate a clinical subgroup of BD patients with ocular disease. As a result, finding a new therapeutic strategy targeting the APRIL pathway might be beneficial in BD patients suffering from ocular involvement.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"314-321"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Attitudes, practices and perceived barriers toward implementing non-pharmacological management for rheumatoid arthritis among rheumatologists: an online cross-sectional survey. 风湿免疫科医生对实施类风湿关节炎非药物治疗的态度、实践和认知障碍:在线横断面调查。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-27 DOI: 10.5114/reum/191792
Fatine Kronbi, Hanan Rkain, Samya Ez-Zaoui, Nada Benzine, Redouane Abouqal, Jihane Belayachi, Najia Hajjaj-Hassouni, Latifa Tahiri, Fadoua Allali

Introduction: Our study aimed to evaluate the integration level of non-pharmacological management (NPM) for rheumatoid arthritis (RA), analyze attitudes, practices, and perceived barriers towards NPM implementation, and identify factors contributing to the underutilization of non-pharmacological treatment in RA.

Material and methods: A descriptive and analytical cross-sectional study was conducted among rheumatologists in Morocco. Rheumatologists received an online questionnaire gathering sociodemographic data, NPM integration level for RA, exploring their attitudes, practices and perceived barriers regarding the integration of NPM for RA, using a Likert scale ranging from 1 to 5. Univariate analyses were conducted to identify risk factors for under-integration of NPM for RA.

Results: Out of 440 questionnaires sent, 132 rheumatologists responded to the survey (mean age of 44 ±12 years, 112 (84.8%) females, median professional experience of 15 years [4.7; 26.3]) with a response rate of 30%. All rheumatologists agreed on the importance of NPM integration into their practice with 130 (98.5%) supporting the necessity of tailored recommendations of NPM of RA for the Moroccan context. Sixty-nine (52.3%) reported a lack of NPM integration for RA. Only 36 (27.3%) consistently provided personalized NPM from RA diagnosis and 47 (35.6%) involved patients in decision-making. Comment perceived barriers included difficulties in organizing multidisciplinary care (122; 92.4%), difficulties with time management in consultation (119; 90.2%), and lack of multidisciplinary team members (116; 87.9%). In univariate analysis, lack of suitable training and lack of knowledge on NPM of RA were risk factors of under-integration of NPM of RA with respectively an odds ratio (OR) of 0.09, 95% CI: 0.01-0.86 and OR of 0.34, 95% CI: 0.15-0.76.

Conclusions: Our study revealed significant insufficiencies in the integration of NPM of RA among Moroccan rheumatologists. Perceived barriers, including insufficient training, lack of knowledge, and infrastructural limitations, hinder effective implementation. Addressing these through tailored education and multidisciplinary collaboration is essential for improving RA management.

导言:我们的研究旨在评估类风湿性关节炎(RA)非药物治疗(NPM)的整合水平,分析实施NPM的态度、实践和感知障碍,并确定导致RA非药物治疗利用不足的因素:在摩洛哥的风湿病学家中开展了一项描述性和分析性横断面研究。风湿病学家收到了一份在线调查问卷,该问卷收集了社会人口学数据、非药物疗法在 RA 中的应用水平,并采用 1-5 分的李克特量表探讨了他们对非药物疗法在 RA 中的应用所持的态度、做法和感知到的障碍。进行了单变量分析,以确定 RA 国家预防机制整合不足的风险因素:在发出的 440 份调查问卷中,132 名风湿免疫科医生(平均年龄为 44 ± 12 岁,112 名(84.8%)女性,专业经验中位数为 15 年 [4.7; 26.3])对调查做出了回复,回复率为 30%。所有风湿病学家都同意将国家预防机制纳入其临床实践的重要性,其中 130 名(98.5%)风湿病学家支持有必要根据摩洛哥的具体情况提出针对 RA 的国家预防机制建议。69名(52.3%)报告称缺乏针对 RA 的国家预防机制整合。只有 36 家医院(27.3%)坚持从 RA 诊断开始提供个性化的 NPM,47 家医院(35.6%)让患者参与决策。评论认为的障碍包括组织多学科护理的困难(122;92.4%)、会诊时间管理的困难(119;90.2%)以及缺乏多学科团队成员(116;87.9%)。在单变量分析中,缺乏适当的培训和缺乏有关 RA 非传染性疾病预防机制的知识是 RA 非传染性疾病预防机制整合不足的风险因素,其几率比(OR)分别为 0.09(95% CI:0.01-0.86)和 0.34(95% CI:0.15-0.76):我们的研究表明,摩洛哥风湿病学家在整合 RA 的国家预防机制方面存在严重不足。培训不足、知识缺乏和基础设施限制等认知障碍阻碍了有效实施。通过有针对性的教育和多学科合作来解决这些问题对于改善 RA 管理至关重要。
{"title":"Attitudes, practices and perceived barriers toward implementing non-pharmacological management for rheumatoid arthritis among rheumatologists: an online cross-sectional survey.","authors":"Fatine Kronbi, Hanan Rkain, Samya Ez-Zaoui, Nada Benzine, Redouane Abouqal, Jihane Belayachi, Najia Hajjaj-Hassouni, Latifa Tahiri, Fadoua Allali","doi":"10.5114/reum/191792","DOIUrl":"https://doi.org/10.5114/reum/191792","url":null,"abstract":"<p><strong>Introduction: </strong>Our study aimed to evaluate the integration level of non-pharmacological management (NPM) for rheumatoid arthritis (RA), analyze attitudes, practices, and perceived barriers towards NPM implementation, and identify factors contributing to the underutilization of non-pharmacological treatment in RA.</p><p><strong>Material and methods: </strong>A descriptive and analytical cross-sectional study was conducted among rheumatologists in Morocco. Rheumatologists received an online questionnaire gathering sociodemographic data, NPM integration level for RA, exploring their attitudes, practices and perceived barriers regarding the integration of NPM for RA, using a Likert scale ranging from 1 to 5. Univariate analyses were conducted to identify risk factors for under-integration of NPM for RA.</p><p><strong>Results: </strong>Out of 440 questionnaires sent, 132 rheumatologists responded to the survey (mean age of 44 ±12 years, 112 (84.8%) females, median professional experience of 15 years [4.7; 26.3]) with a response rate of 30%. All rheumatologists agreed on the importance of NPM integration into their practice with 130 (98.5%) supporting the necessity of tailored recommendations of NPM of RA for the Moroccan context. Sixty-nine (52.3%) reported a lack of NPM integration for RA. Only 36 (27.3%) consistently provided personalized NPM from RA diagnosis and 47 (35.6%) involved patients in decision-making. Comment perceived barriers included difficulties in organizing multidisciplinary care (122; 92.4%), difficulties with time management in consultation (119; 90.2%), and lack of multidisciplinary team members (116; 87.9%). In univariate analysis, lack of suitable training and lack of knowledge on NPM of RA were risk factors of under-integration of NPM of RA with respectively an odds ratio (OR) of 0.09, 95% CI: 0.01-0.86 and OR of 0.34, 95% CI: 0.15-0.76.</p><p><strong>Conclusions: </strong>Our study revealed significant insufficiencies in the integration of NPM of RA among Moroccan rheumatologists. Perceived barriers, including insufficient training, lack of knowledge, and infrastructural limitations, hinder effective implementation. Addressing these through tailored education and multidisciplinary collaboration is essential for improving RA management.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 4","pages":"250-258"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-traumatic spinal cord injury - etiological profile and associated factors: single rheumatological center experience. 非创伤性脊髓损伤--病因概况和相关因素:单一风湿病中心的经验。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-16 DOI: 10.5114/reum/191753
Yannick L T Bayala, Ismael Ayouba Tinni, Fulgence Kaboré, Aboubakar Ouédraogo, Enselme Y Zongo, Marcellin Bonkoungou, Joëlle Wendlassida Stéphanie Zabsonré-Tiendrebeogo, Dieu-Donné Ouédraogo

Introduction: Non-traumatic spinal cord injury (NTSCI) represents a medical-surgical emergency. In Burkina Faso, limited data exist on the etiological profiles of this syndrome in rheumatology. This study aimed to describe the etiological profile of NTSCI in the Rheumatology Department of the University Hospital Center of Bogodogo (CHU-B).

Material and methods: This was a cross-sectional, retrospective study with descriptive and analytical aims, conducted from March 1, 2017, to December 31, 2023, in the Rheumatology Department of CHU-B. Patients diagnosed with non-traumatic spinal cord compression syndrome during hospitalization were included.

Results: The frequency in the Rheumatology Department of NTSCI was 2.94%, accounting for 104 patients. There were 68 men (65.38%), with a sex ratio of 1.88. The average age of the population was 57.91 years. All patients experienced back pain, with a lumbar location in 77 patients (74.04%). The average duration of the motor deficit was 2.97 months. A total of 3,532 patients were admitted to the conventional hospitalization unit of the Rheumatology Department at the CHU-B from March 1, 2017, to December 31, 2023. Among these, 104 patients had NTSCI, yielding a frequency of 2.94%. Spinal MRI was performed in 58 patients (55.77%), and the compression was extradural in 76.92% of cases (n = 80). The etiologies identified were Pott's disease in 32 patients (30.77%), followed by spinal metastases in 22 patients (21.15%). Twenty-nine patients (27.89%) experienced complications related to prolonged bed rest. No factor was significantly associated with the recovery of the motor deficit.

Conclusions: Non-traumatic spinal cord injury is relatively rare in rheumatological practice in Ouagadougou. The etiology is predominantly Pott's disease, which confirms the geographical distribution of NTSCI causes.

简介非创伤性脊髓损伤(NTSCI)是一种内外科急症。在布基纳法索,风湿病学中有关该综合征病因的数据十分有限。本研究旨在描述博戈多戈大学中心医院(CHU-B)风湿病科 NTSCI 的病因概况:这是一项横断面回顾性研究,以描述和分析为目的,于2017年3月1日至2023年12月31日在CHU-B风湿病科进行。研究纳入了住院期间诊断为非创伤性脊髓压迫综合征的患者:非外伤性脊髓压迫综合征在风湿病科的发病率为2.94%,共有104名患者。其中男性 68 人(65.38%),性别比为 1.88。平均年龄为 57.91 岁。所有患者均有背痛症状,其中 77 名患者(74.04%)的疼痛部位为腰部。运动障碍的平均持续时间为 2.97 个月。从2017年3月1日到2023年12月31日,共有3532名患者在CHU-B风湿病科常规住院部住院治疗。其中,104名患者患有NTSCI,发病率为2.94%。58名患者(55.77%)接受了脊柱核磁共振检查,76.92%的病例(n = 80)出现硬膜外压迫。32名患者(30.77%)的病因是波特氏病,22名患者(21.15%)的病因是脊柱转移瘤。29名患者(27.89%)出现了与长期卧床有关的并发症。没有任何因素与运动障碍的恢复明显相关:结论:非创伤性脊髓损伤在瓦加杜古的风湿病治疗中较为罕见。病因主要是波特氏病,这证实了非创伤性脊髓损伤病因的地理分布。
{"title":"Non-traumatic spinal cord injury - etiological profile and associated factors: single rheumatological center experience.","authors":"Yannick L T Bayala, Ismael Ayouba Tinni, Fulgence Kaboré, Aboubakar Ouédraogo, Enselme Y Zongo, Marcellin Bonkoungou, Joëlle Wendlassida Stéphanie Zabsonré-Tiendrebeogo, Dieu-Donné Ouédraogo","doi":"10.5114/reum/191753","DOIUrl":"https://doi.org/10.5114/reum/191753","url":null,"abstract":"<p><strong>Introduction: </strong>Non-traumatic spinal cord injury (NTSCI) represents a medical-surgical emergency. In Burkina Faso, limited data exist on the etiological profiles of this syndrome in rheumatology. This study aimed to describe the etiological profile of NTSCI in the Rheumatology Department of the University Hospital Center of Bogodogo (CHU-B).</p><p><strong>Material and methods: </strong>This was a cross-sectional, retrospective study with descriptive and analytical aims, conducted from March 1, 2017, to December 31, 2023, in the Rheumatology Department of CHU-B. Patients diagnosed with non-traumatic spinal cord compression syndrome during hospitalization were included.</p><p><strong>Results: </strong>The frequency in the Rheumatology Department of NTSCI was 2.94%, accounting for 104 patients. There were 68 men (65.38%), with a sex ratio of 1.88. The average age of the population was 57.91 years. All patients experienced back pain, with a lumbar location in 77 patients (74.04%). The average duration of the motor deficit was 2.97 months. A total of 3,532 patients were admitted to the conventional hospitalization unit of the Rheumatology Department at the CHU-B from March 1, 2017, to December 31, 2023. Among these, 104 patients had NTSCI, yielding a frequency of 2.94%. Spinal MRI was performed in 58 patients (55.77%), and the compression was extradural in 76.92% of cases (<i>n</i> = 80). The etiologies identified were Pott's disease in 32 patients (30.77%), followed by spinal metastases in 22 patients (21.15%). Twenty-nine patients (27.89%) experienced complications related to prolonged bed rest. No factor was significantly associated with the recovery of the motor deficit.</p><p><strong>Conclusions: </strong>Non-traumatic spinal cord injury is relatively rare in rheumatological practice in Ouagadougou. The etiology is predominantly Pott's disease, which confirms the geographical distribution of NTSCI causes.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 4","pages":"259-265"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis. 类风湿性关节炎患者利妥昔单抗治疗反应的常规临床实践早期预测因素。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.5114/reum/189780
Evgenija Mihajloska, Aleksandar Dimkovski, Aleksandra Grozdanova, Ana Vasilevska, Dubravka Antova, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Bashkim Osmani, Ljubica Shuturkova

Introduction: Identifying early predictive factors of how rheumatoid arthritis (RA) patients respond to rituximab (RTX) treatment is crucial for both individual treatment outcome and the improvement of clinical practice overall. This study aimed to identify early predictive factors available in standard clinical practice for predicting RTX treatment outcomes in RA patients.

Material and methods: Data on seventy patients diagnosed with RA treated with RTX (two 1,000 mg doses 2 weeks apart or two 500 mg doses 2 weeks apart) were retrospectively collected. Baseline information collected at the initiation of RTX treatment included patient characteristics such as age, sex, disease duration, disease activity, Health Assessment Questionnaire score, erythrocyte sedimentation rate, C-reactive protein, and serological status regarding rheumatoid factor (RF) and anti-cyclic citrullinated protein antibodies (ACPA). Clinical responses were analyzed 6 months after RTX initiation using the European Alliance of Associations for Rheumatology criteria. Potential predictors associated with positive RTX response at 6 months were identified using a multivariate ordinal logistic regression model.

Results: The analysis showed that persistently active RA disease, Disease Activity Score with 28-joint count (DAS28) values at the treatment onset and after 3 months, along with erythrocyte sedimentation rate at treatment initiation, were negatively correlated with the response to RTX therapy (p < 0.05). All these correlations were statistically significant at the 99% confidence interval. The correlation and logistic regression analyses indicate that there are no significant association between RF and ACPA concerning therapy response, despite a higher number of RTX responders in the seropositive groups. Additionally, the study emphasizes the prognostic significance of the DAS28 value at treatment initiation in predicting therapy response at 6 months.

Conclusions: The optimal model for predicting RTX response at 6 months involves the interaction of all clinical factors examined in this study, as revealed by the analysis of multiple variables.

导言:确定类风湿性关节炎(RA)患者对利妥昔单抗(RTX)治疗反应的早期预测因素对于个体治疗效果和临床实践的整体改进都至关重要。本研究旨在确定标准临床实践中可用于预测RA患者RTX治疗结果的早期预测因素:回顾性收集了70例接受RTX治疗(两次1000毫克剂量,间隔2周;或两次500毫克剂量,间隔2周)的RA患者的数据。开始 RTX 治疗时收集的基线信息包括患者特征,如年龄、性别、病程、疾病活动度、健康评估问卷评分、红细胞沉降率、C 反应蛋白以及类风湿因子(RF)和抗环瓜氨酸蛋白抗体(ACPA)的血清学状态。根据欧洲风湿病学协会联盟的标准,对开始使用 RTX 6 个月后的临床反应进行了分析。使用多变量序数逻辑回归模型确定了与6个月后RTX阳性反应相关的潜在预测因素:分析结果显示,持续活动的RA疾病、治疗开始时和3个月后的疾病活动度评分(DAS28)值以及治疗开始时的红细胞沉降率与RTX治疗反应呈负相关(P < 0.05)。所有这些相关性在 99% 的置信区间内均有统计学意义。相关性分析和逻辑回归分析表明,尽管血清反应阳性组中有较多的 RTX 反应者,但 RF 和 ACPA 与治疗反应之间并无明显关联。此外,该研究还强调了开始治疗时的 DAS28 值对预测 6 个月后治疗反应的预后意义:多变量分析显示,预测 6 个月后 RTX 反应的最佳模型涉及本研究中所有临床因素的相互作用。
{"title":"Early predictive factors in routine clinical practice for rituximab therapy response in patients with rheumatoid arthritis.","authors":"Evgenija Mihajloska, Aleksandar Dimkovski, Aleksandra Grozdanova, Ana Vasilevska, Dubravka Antova, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Bashkim Osmani, Ljubica Shuturkova","doi":"10.5114/reum/189780","DOIUrl":"10.5114/reum/189780","url":null,"abstract":"<p><strong>Introduction: </strong>Identifying early predictive factors of how rheumatoid arthritis (RA) patients respond to rituximab (RTX) treatment is crucial for both individual treatment outcome and the improvement of clinical practice overall. This study aimed to identify early predictive factors available in standard clinical practice for predicting RTX treatment outcomes in RA patients.</p><p><strong>Material and methods: </strong>Data on seventy patients diagnosed with RA treated with RTX (two 1,000 mg doses 2 weeks apart or two 500 mg doses 2 weeks apart) were retrospectively collected. Baseline information collected at the initiation of RTX treatment included patient characteristics such as age, sex, disease duration, disease activity, Health Assessment Questionnaire score, erythrocyte sedimentation rate, C-reactive protein, and serological status regarding rheumatoid factor (RF) and anti-cyclic citrullinated protein antibodies (ACPA). Clinical responses were analyzed 6 months after RTX initiation using the European Alliance of Associations for Rheumatology criteria. Potential predictors associated with positive RTX response at 6 months were identified using a multivariate ordinal logistic regression model.</p><p><strong>Results: </strong>The analysis showed that persistently active RA disease, Disease Activity Score with 28-joint count (DAS28) values at the treatment onset and after 3 months, along with erythrocyte sedimentation rate at treatment initiation, were negatively correlated with the response to RTX therapy (<i>p</i> < 0.05). All these correlations were statistically significant at the 99% confidence interval. The correlation and logistic regression analyses indicate that there are no significant association between RF and ACPA concerning therapy response, despite a higher number of RTX responders in the seropositive groups. Additionally, the study emphasizes the prognostic significance of the DAS28 value at treatment initiation in predicting therapy response at 6 months.</p><p><strong>Conclusions: </strong>The optimal model for predicting RTX response at 6 months involves the interaction of all clinical factors examined in this study, as revealed by the analysis of multiple variables.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 3","pages":"150-156"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of periodontal status in Polish patients with rheumatoid arthritis treated with biological therapies. 对接受生物疗法治疗的波兰类风湿关节炎患者的牙周状况进行分析。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-09 DOI: 10.5114/reum/194593
Joanna Samborska-Mazur, Dorota Sikorska, Marzena Liliana Wyganowska

Introduction: Periodontitis, characterized by inflammation affecting the tooth-supporting tissues, may increase the risk of rheumatoid arthritis (RA) or cardiovascular diseases. The aim of the study was to evaluate the periodontal status in RA patients and its impact on the inflammatory markers and red cell parameters obtained from complete blood laboratory tests to study the risk of cardiovascular disease development.

Material and methods: The cross-sectional study included 50 patients with RA treated with biological therapies: tumor necrosis factor inhibitors, interleukin-6 blockers. Rheumatoid arthritis disease activity was assessed with Disease Activity Score with 28-joint count (DAS28). The periodontal indices modified Approximal Periodontal Index, modified Papillary Bleeding Index, and Periodontal Screening Index (PSI) were used to assess patients' periodontal status. Serum levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were used as inflammatory markers and a potential cardiovascular risk factor.

Results: No statistically significant correlation was found between the periodontal status and RA activity. However, a statistically significant correlation was found between the CRP results and the PSI scores (R = -0.264510, p = 0.048837). Evaluation of the red cell parameters showed statistically significant differences in the markers of inflammation ESR (R = 0.369398, p = 0.008289) and CRP (R = 0.367405, p = 0.008672). Red cell distribution width values were also correlated with RA activity (R = 0.286387, p = 0.043769) and duration of the disease (R = 0.339425, p = 0.015889).

Conclusions: A satisfactory periodontal status was found in most of the study group. Increased CRP levels in patients with periodontitis may indicate the negative impact of periodontal status on the general clinical condition of the patient.

导言:牙周炎的特点是影响牙齿支撑组织的炎症,可能增加类风湿关节炎(RA)或心血管疾病的风险。本研究的目的是评估RA患者的牙周状况及其对全血实验室检查获得的炎症标志物和红细胞参数的影响,以研究心血管疾病发展的风险。材料与方法:横断面研究纳入50例RA患者,采用生物疗法:肿瘤坏死因子抑制剂、白细胞介素-6阻滞剂。类风湿关节炎疾病活动性采用28关节计数疾病活动性评分(DAS28)进行评估。采用改良牙周指数、改良乳头状出血指数和牙周筛查指数(PSI)评估患者牙周状况。血清红细胞沉降率(ESR)和c反应蛋白(CRP)水平被用作炎症标志物和潜在的心血管危险因素。结果:牙周状况与RA活动度无统计学意义。然而,CRP结果与PSI评分之间存在统计学意义上的相关性(R = -0.264510, p = 0.048837)。评价红细胞参数时,炎症指标ESR (R = 0.369398, p = 0.008289)和CRP (R = 0.367405, p = 0.008672)差异有统计学意义。红细胞分布宽度值也与RA活度(R = 0.286387, p = 0.043769)和病程(R = 0.339425, p = 0.015889)相关。结论:大多数研究对象牙周状况良好。牙周炎患者CRP水平升高可能表明牙周状况对患者一般临床状况的负面影响。
{"title":"Analysis of periodontal status in Polish patients with rheumatoid arthritis treated with biological therapies.","authors":"Joanna Samborska-Mazur, Dorota Sikorska, Marzena Liliana Wyganowska","doi":"10.5114/reum/194593","DOIUrl":"10.5114/reum/194593","url":null,"abstract":"<p><strong>Introduction: </strong>Periodontitis, characterized by inflammation affecting the tooth-supporting tissues, may increase the risk of rheumatoid arthritis (RA) or cardiovascular diseases. The aim of the study was to evaluate the periodontal status in RA patients and its impact on the inflammatory markers and red cell parameters obtained from complete blood laboratory tests to study the risk of cardiovascular disease development.</p><p><strong>Material and methods: </strong>The cross-sectional study included 50 patients with RA treated with biological therapies: tumor necrosis factor inhibitors, interleukin-6 blockers. Rheumatoid arthritis disease activity was assessed with Disease Activity Score with 28-joint count (DAS28). The periodontal indices modified Approximal Periodontal Index, modified Papillary Bleeding Index, and Periodontal Screening Index (PSI) were used to assess patients' periodontal status. Serum levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were used as inflammatory markers and a potential cardiovascular risk factor.</p><p><strong>Results: </strong>No statistically significant correlation was found between the periodontal status and RA activity. However, a statistically significant correlation was found between the CRP results and the PSI scores (<i>R</i> = -0.264510, <i>p</i> = 0.048837). Evaluation of the red cell parameters showed statistically significant differences in the markers of inflammation ESR (<i>R</i> = 0.369398, <i>p</i> = 0.008289) and CRP (<i>R</i> = 0.367405, <i>p</i> = 0.008672). Red cell distribution width values were also correlated with RA activity (<i>R</i> = 0.286387, <i>p</i> = 0.043769) and duration of the disease (<i>R</i> = 0.339425, <i>p</i> = 0.015889).</p><p><strong>Conclusions: </strong>A satisfactory periodontal status was found in most of the study group. Increased CRP levels in patients with periodontitis may indicate the negative impact of periodontal status on the general clinical condition of the patient.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"351-359"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature. 感染因子和风湿性多肌痛:从已发表文献的叙述性回顾中出现的关键讨论点。
IF 1.4 Q3 RHEUMATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-11-06 DOI: 10.5114/reum/194687
Ciro Manzo, Marco Isetta, Alberto Castagna

Introduction: The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases of PMR following the coronavirus disease 2019 (COVID-19) have revived the role of infection as an aetiological or triggering factor. It is estimated that patients with PMR have manifestations of giant cell arteritis (GCA) in < 20% of cases. To date, little is known on the potential role of infectious agents in facilitating this association. Given this background, we performed a review of published literature. Our first aim was to review and discuss the relationship between PMR and infective agents. Secondly, we compared data of PMR-only patients with PMR and overlapping GCA to seek any commonalities or differences regarding the type of infectious agent in these two subgroups.

Material and methods: We performed a non-systematic literature search on Embase and Medline (COVID interface) with the following search terms: "polymyalgia rheumatica" AND "infections" OR "infectious agents", both MESH headings and free-text (in each language they were written). Each paper's reference list was scanned for additional publications meeting this study's aim. When papers reported data partially presented in previous articles, we referred to the most recent published data. Abstracts submitted at conferences or from non-peer-reviewed sources were not included. Polymyalgia rheumatica following vaccinations was an additional exclusion criterion.

Results: Several infectious agents have been held responsible for PMR. However, no definite causal link has been identified so far. According to our review, the search for a specific infectious agent, however intriguing, appears to be stagnating. Genetic background and epigenetic regulation probably play a key role. However, topical studies are lacking. Polymyalgia rheumatica as an adverse event following immunization should be kept methodologically distinct from PMR following an acute infection, as the adjuvants in the vaccine can make a significant difference.

Conclusions: Finally, some infectious agents are able to replicate in human arteries or have an endothelium tropism. Whilst these can theoretically trigger GCA, their role in isolated PMR seems minimal.

多肌痛风湿病(PMR)的病因尚不清楚。最近,关于2019年冠状病毒病(COVID-19)后PMR病例的报告再次强调了感染作为病因或触发因素的作用。据估计,小于20%的PMR患者有巨细胞动脉炎(GCA)的表现。迄今为止,对感染因子在促进这种关联中的潜在作用知之甚少。在此背景下,我们对已发表的文献进行了回顾。我们的第一个目的是回顾和讨论PMR与感染因子之间的关系。其次,我们比较了仅PMR患者的PMR和重叠GCA的数据,以寻找这两个亚组中感染因子类型的共同点或差异。材料和方法:我们在Embase和Medline (COVID界面)上进行了非系统的文献检索,检索词为:“风湿性多肌痛”和“感染”或“感染因子”,包括MESH标题和自由文本(每种语言)。扫描每篇论文的参考文献列表,寻找符合本研究目的的其他出版物。当论文报告的数据部分出现在以前的文章中时,我们参考了最近发表的数据。在会议上提交的摘要或来自非同行评议来源的摘要未包括在内。接种疫苗后风湿多肌痛是另一个排除标准。结果:PMR是由几种感染因子引起的。然而,到目前为止,还没有确定的因果关系。根据我们的回顾,寻找一种特定的感染因子,无论多么有趣,似乎停滞不前。遗传背景和表观遗传调控可能起关键作用。然而,缺乏专题研究。风湿多肌痛作为免疫接种后的不良事件,应在方法上与急性感染后的PMR区分开来,因为疫苗中的佐剂可以产生显着差异。结论:最后,一些感染因子能够在人动脉中复制或具有内皮性。虽然这些在理论上可以触发GCA,但它们在孤立的PMR中的作用似乎微乎其微。
{"title":"Infective agents and polymyalgia rheumatica: key discussion points emerging from a narrative review of published literature.","authors":"Ciro Manzo, Marco Isetta, Alberto Castagna","doi":"10.5114/reum/194687","DOIUrl":"10.5114/reum/194687","url":null,"abstract":"<p><strong>Introduction: </strong>The aetiology of polymyalgia rheumatica (PMR) is unknown. Recently, reports on cases of PMR following the coronavirus disease 2019 (COVID-19) have revived the role of infection as an aetiological or triggering factor. It is estimated that patients with PMR have manifestations of giant cell arteritis (GCA) in < 20% of cases. To date, little is known on the potential role of infectious agents in facilitating this association. Given this background, we performed a review of published literature. Our first aim was to review and discuss the relationship between PMR and infective agents. Secondly, we compared data of PMR-only patients with PMR and overlapping GCA to seek any commonalities or differences regarding the type of infectious agent in these two subgroups.</p><p><strong>Material and methods: </strong>We performed a non-systematic literature search on Embase and Medline (COVID interface) with the following search terms: \"polymyalgia rheumatica\" AND \"infections\" OR \"infectious agents\", both MESH headings and free-text (in each language they were written). Each paper's reference list was scanned for additional publications meeting this study's aim. When papers reported data partially presented in previous articles, we referred to the most recent published data. Abstracts submitted at conferences or from non-peer-reviewed sources were not included. Polymyalgia rheumatica following vaccinations was an additional exclusion criterion.</p><p><strong>Results: </strong>Several infectious agents have been held responsible for PMR. However, no definite causal link has been identified so far. According to our review, the search for a specific infectious agent, however intriguing, appears to be stagnating. Genetic background and epigenetic regulation probably play a key role. However, topical studies are lacking. Polymyalgia rheumatica as an adverse event following immunization should be kept methodologically distinct from PMR following an acute infection, as the adjuvants in the vaccine can make a significant difference.</p><p><strong>Conclusions: </strong>Finally, some infectious agents are able to replicate in human arteries or have an endothelium tropism. Whilst these can theoretically trigger GCA, their role in isolated PMR seems minimal.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"62 5","pages":"360-367"},"PeriodicalIF":1.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1